Mineralys Therapeutics, Inc.MLYS stock score: 31/100
$14.16 · +2.76% · Scored Nov 19, 2026
- Technical
- 23
- Fundamental
- 33
- News
- —
The reading
Mineralys Therapeutics (MLYS) scores 31 out of 100, which reads bearish, higher than 5% of Healthcare stocks and 6% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 33, technicals 23.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Free Cash Flow Yield at 0 weighs the most against it.
On the daily chart, trend-following indicators average 10 and contrarian oscillators 73 — a split worth reading before trusting the technical total.
Since Aug 22, 2026 the composite has ranged from 30 to 48, and it is down 12 points over the period.
About Mineralys Therapeutics
Mineralys Therapeutics (MLYS) is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease and related conditions driven by excess aldosterone, a hormone that raises blood pressure. Its lead candidate, lorundrostat, is a once-daily oral drug designed to block aldosterone synthase, the enzyme that makes aldosterone, while largely sparing production of cortisol. In late-stage trials, lorundrostat lowered blood pressure in adults with uncontrolled or resistant hypertension when added to existing medicines, and it has also been studied in patients with chronic kidney disease. A trial in obstructive sleep apnea did not meet its main goal. Mineralys has no product revenue and funds operations with cash raised from investors.
In hypertension, Mineralys would compete with many generic blood pressure drugs and with AstraZeneca’s baxdrostat, another aldosterone synthase inhibitor, as well as with other new treatments for resistant hypertension. Its edge rests on a selective mechanism that targets a common cause of hard-to-control high blood pressure and on data from several positive trials. Investors who follow MLYS stock tend to watch the regulatory process and commercial plans for lorundrostat. Data in kidney disease and other indications are closely followed. Partnering, pricing, competition from baxdrostat and cash runway are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward MLYS’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
33Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
19Pulling it up
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
- RSI (14)92
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.
Holding it back
S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.
The price change over the last 52 weeks.
Where the price sits between its 52-week low and high.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 38 | 1 |
| Daily | 19 | 3 |
| Weekly | 22 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 31 |
| Nov 18, 2026 | 30 |
| Nov 17, 2026 | 31 |
| Nov 16, 2026 | 31 |
| Nov 15, 2026 | 32 |
| Nov 14, 2026 | 32 |
| Nov 13, 2026 | 32 |
| Nov 12, 2026 | 30 |
| Nov 11, 2026 | 33 |
| Nov 10, 2026 | 32 |
| Nov 8, 2026 | 31 |
| Nov 7, 2026 | 31 |
| Nov 6, 2026 | 31 |
| Nov 5, 2026 | 30 |
| Nov 4, 2026 | 32 |
| Nov 3, 2026 | 31 |
| Nov 2, 2026 | 31 |
| Nov 1, 2026 | 33 |
| Oct 31, 2026 | 32 |
| Oct 30, 2026 | 31 |
| Oct 29, 2026 | 35 |
| Oct 28, 2026 | 34 |
| Oct 27, 2026 | 35 |
| Oct 26, 2026 | 33 |
| Oct 25, 2026 | 34 |
| Oct 24, 2026 | 33 |
| Oct 23, 2026 | 33 |
| Oct 22, 2026 | 35 |
| Oct 21, 2026 | 34 |
| Oct 20, 2026 | 34 |
| Oct 19, 2026 | 34 |
| Oct 18, 2026 | 33 |
| Oct 17, 2026 | 33 |
| Oct 16, 2026 | 32 |
| Oct 15, 2026 | 34 |
| Oct 14, 2026 | 33 |
| Oct 13, 2026 | 33 |
| Oct 12, 2026 | 34 |
| Oct 11, 2026 | 36 |
| Oct 10, 2026 | 36 |
| Oct 9, 2026 | 36 |
| Oct 8, 2026 | 35 |
| Oct 7, 2026 | 34 |
| Oct 6, 2026 | 34 |
| Oct 5, 2026 | 35 |
| Oct 4, 2026 | 36 |
| Oct 3, 2026 | 36 |
| Oct 2, 2026 | 35 |
| Oct 1, 2026 | 35 |
| Sep 30, 2026 | 37 |
| Sep 29, 2026 | 36 |
| Sep 28, 2026 | 37 |
| Sep 27, 2026 | 37 |
| Sep 26, 2026 | 38 |
| Sep 25, 2026 | 36 |
| Sep 24, 2026 | 40 |
| Sep 23, 2026 | 44 |
| Sep 22, 2026 | 46 |
| Sep 21, 2026 | 44 |
| Sep 20, 2026 | 43 |
| Sep 19, 2026 | 43 |
| Sep 18, 2026 | 42 |
| Sep 17, 2026 | 43 |
| Sep 16, 2026 | 42 |
| Sep 15, 2026 | 45 |
| Sep 14, 2026 | 45 |
| Sep 13, 2026 | 44 |
| Sep 12, 2026 | 44 |
| Sep 11, 2026 | 44 |
| Sep 10, 2026 | 45 |
| Sep 9, 2026 | 47 |
| Sep 8, 2026 | 48 |
| Sep 7, 2026 | 44 |
| Sep 6, 2026 | 46 |
| Sep 5, 2026 | 46 |
| Sep 4, 2026 | 45 |
| Sep 3, 2026 | 46 |
| Sep 2, 2026 | 46 |
| Sep 1, 2026 | 41 |
| Aug 31, 2026 | 39 |
| Aug 30, 2026 | 38 |
| Aug 29, 2026 | 39 |
| Aug 28, 2026 | 41 |
| Aug 27, 2026 | 44 |
| Aug 26, 2026 | 43 |
| Aug 25, 2026 | 43 |
| Aug 24, 2026 | 42 |
| Aug 23, 2026 | 43 |
| Aug 22, 2026 | 43 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.82
- Risk grade (1–10)
- 9
- Next earnings
- Nov 4, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| GHRS GH Research | $1.3B | 42 |
| NVAX Novavax | $1.3B | 55 |
| MNKD MannKind | $1.3B | 56 |
| SLN Silence Therapeutics | $1.2B | 55 |
| TSHA Taysha Gene Therapies | $1.2B | 47 |
| GPCR Structure Therapeutics | $1.2B | 29 |
Questions
What is MLYS's stock rating today?
MLYS scores 31/100 (Bearish) as of Nov 19, 2026: technical 23, fundamental 33. Scores are recomputed every night.
What does Mineralys Therapeutics do?
Mineralys Therapeutics (MLYS) is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease and related conditions driven by excess aldosterone, a hormone that raises blood pressure. Its lead candidate, lorundrostat, is a once-daily oral drug designed to block aldosterone synthase, the enzyme that makes aldosterone, while largely sparing production of cortisol.
Is MLYS stock a buy?
The score is not a buy or sell recommendation. A 31 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the MLYS score calculated?
88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/mlys/"><img src="https://stocksscores.com/stocks/mlys/badge.svg" alt="MLYS stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/mlys/)